months). Both enzymes were negatively expressed in PrECs andPrSCs at mRNA and protein levels. ATX expression was higher than AGK in AILNCaP, DU-145, and PC-3 cell-lines, while AGK was mainly expressed in LNCaP cells. Immunohistochemically, ATX and AGK expressions were negative in non-neoplastic epithelia, while both were weakly expressed in the majority of high-grade intra-epithelial neoplasia (HG-PIN). In cancer foci, ATX and AGK expressions were strong in 49% and 62%, weak in 40% and 32%, and negative in 11% and 6%, respectively. Expressions of both enzymes were significantly correlated with primary Gleason grade of cancer foci (P < 0.0001) and capsular invasion (P = 0.03 and 0.003 respectively). ATX expression was significantly correlated with probability of prostate specific antigen (PSA)-failure after surgery (P < 0.0001). In conclusion, LPA-producing enzymes (ATX and AGK) were frequently expressed in prostate cancer cells and precancerous HG-PIN. In particular, high expression levels of ATX were associated with both malignant potentials and poor outcomes. (Cancer Sci 2009; 100: 1631-1638) L ysophosphatidic acid (1-or 2-acyl-lysophosphatidic acid; LPA) is an extracellular bioactive phospholipid that mediates diverse biological activities including platelet aggregation, smooth muscle contraction, cancer cell proliferation, invasion, angiogenesis, and cytoskeletal reorganization.(1,2) This action is mediated by several interactive mechanisms: (a) It activates RhoA and NF-κβ genes inducing prostate cancer progression. (3,4) (b) It enhances SRE activity in promoters of immediate early growth-related genes.(5) (c) It stimulates secretion of polypeptide growth factors such as EGF (epidermal growth factor) and sensitizes cells to their growth promoting effects.(6,7) (d) Finally, LPA suppresses apoptosis of cancer cells by reducing levels of apoptosispromoting proteins. (8,9) We previously examined LPA activity in various biologic fluids and found a high LPA activity exerted by a specific type of its receptors (Edg-7/LPA3) in human seminal fluids.(10) Furthermore, addition of 18:1 LPA (oleoyl-LPA) to prostate epithelial and stromal cells resulted in up-regulation of a novel extracellular matrix signaling protein CYR-61, that has a growth stimulating potential. (11) Several routes are proposed for LPA production. It is produced extracellularly by lipoprotein oxidation through the action of secretory phospholipase A2 on microvesicles released from activated cells. (12) In plasma, it is produced by thrombin-activated platelets through the stimulated release of phospholipase-A1 and A2 (13) and lysophospholipase D (LysoPLD). (14,15) LysoPLD is identical to autotaxin (nucleotide pyrophosphatase phosphodiesterase-2; ATX/NPP2, EC 3.1.1.5), a cell motility-stimulating factor originally identified in the culture cell supernatant of malignant melanoma cells. (16,17) We previously found that human seminal fluids contain a large amount of ATX, which hydrolyses lysophosphatidylcholine to produce LPA.(18) While LPA signaling had ...
By acting via LPA3, LPA may play an important role in the development of prostate cancer. Switching of LPA receptor expression from LPA3 to LPA1, may be involved in prostate cancer progression and/or androgen independence. LPA may also play a key role in the development of benign prostatic hyperplasia.
Renal cell carcinoma (RCC) is one of the most drug-resistant malignancies in humans. We show that adriamycin (ADR) and TNF-related apoptosis-inducing ligand (TRAIL)/ Apo2L have a synergistic cytotoxic effect against RCC cells. This synergistic cytotoxicity was obtained in ACHN, A704, Caki-1 and Caki-2 human RCC cell lines and freshly derived RCC cells from 6 patients. This synergistic effect, however, was not achieved in 5 samples of freshly isolated normal kidney cells. We further explored the mechanisms underlying this synergistic effect and found that the synergistic cytotoxicity of TRAIL/Apo2L and ADR was realized by inducing apoptosis. Sequential treatment with ADR followed by TRAIL/Apo2L induced significantly more cytotoxicity than the reverse treatment. ADR increased the expression of DR4 and DR5 in RCC cells, but not in the normal kidney cells. Furthermore, the synergistic cytotoxicity was significantly inhibited by DR4:Fc and DR5:Fc fusion proteins, which inhibit TRAIL/Apo2L-mediated apoptosis. In addition, caspase activity assays and treatment of caspase inhibitors demonstrated that the combination treatment with ADR and TRAIL/ Apo2L activated caspase cascade, including caspase-9, -8, -6 and -3, which were the downstream molecules of death receptors. These findings indicate that ADR sensitizes RCC cells to TRAIL/Apo2L-mediated apoptosis through induction of DR4 and DR5, suggesting that the combination therapy of TRAIL/Apo2L and ADR might be effective for RCC therapy.
Although the clinical implications of the over expression of uroplakin III and III-delta4 in nonulcerative interstitial cystitis bladders remains to be clarified, from the diagnostic viewpoint uroplakin III-delta4 is a potential marker for identifying nonulcerative interstitial cystitis.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.